Further, reflecting both inflammatory activity and macrophage-driven pro-fibrotic signaling, Galectin-3 has been associated with adverse outcomes in patients with overt HFpEF, while elevated levels are also frequently observed in individuals with T2DM [9]. This evidence concerns the gene LGALS3 and type 2 diabetes mellitus.